Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan-Reference-Cited by-同舟云学术

Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan

Published:2017-04-21 Issue:8 Volume:18 Page:753-758
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Tsuji Yasushi¹,Baba Hideo²,Takeda Koji³,Kobayashi Michiya⁴,Oki Eiji⁵,Gotoh Masahiro⁶,Yoshida Kazuhiro⁷,Shimokawa Mototsugu⁸,Kakeji Yoshihiro⁹,Aiba Keisuke¹⁰

Affiliation:

1. Department of Medical Oncology, Tonan Hospital, Sapporo, Japan

2. Department of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan

3. Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan

4. Cancer Treatment Center, Kochi Medical School Hospital, Nankoku, Japan

5. Department of Surgery and Science, Kyushu University, Fukuoka, Japan

6. Cancer Chemotherapy Center, Osaka Medical College Hospital, Takatsuki, Japan

7. Department of Surgical Oncology, Gifu University, Gifu, Japan

8. Department of Cancer Information Research, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

9. Division of Gastrointestinal Surgery, Kobe University Hospital, Kobe, Japan

10. Department of Internal Medicine, Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, Tokyo, Japan

Funder

Co-operative Clinical Research (CSP-CCR) of Public Health Research Foundation

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2017.1317746

Reference18 articles.

1. Modulation of Fluorouracil by Leucovorin in Patients With Advanced Colorectal Cancer: An Updated Meta-Analysis

2. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

3. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

4. Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials

5. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials;Cancer Management and Research;2024-04

2. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)—a systematic review and individual patient data meta-analysis;Supportive Care in Cancer;2023-08

3. Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy;Cancer Management and Research;2022-09

4. The efficacy of single dose palonosetron in highly emetogenic chemotherapy protocols compared to oral aprepitant and ondansetron;Journal of Pharmacovigilance and Drug Research;2022-09-01

5. One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis;The Oncologist;2022-04-15